Cita APA (7a ed.)

Tsuzuki, S., Nakanishi, S., Tamaki, M., Oshiro, T., Miki, J., Yamada, H., . . . Egawa, S. (2021). Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer. Public Library of Science (PLoS).

Cita Chicago Style (17a ed.)

Tsuzuki, Shunsuke, et al. Initial Dose Reduction of Enzalutamide Does Not Decrease the Incidence of Adverse Events in Castration-resistant Prostate Cancer. Public Library of Science (PLoS), 2021.

Cita MLA (8a ed.)

Tsuzuki, Shunsuke, et al. Initial Dose Reduction of Enzalutamide Does Not Decrease the Incidence of Adverse Events in Castration-resistant Prostate Cancer. Public Library of Science (PLoS), 2021.